Speakers
Poul Sørensen
Professor, Chief Scientific Officer & Co-Founder
Allero Therapeutics
Day Two
Thursday – January 27, 2022
10:00 am | Harnessing the Oral Mucosa for Antigen-Specific Immunotherapy of Immune Disorders
Andreas Lutterotti
Chief Medical Officer
Cellerys
Day Two
Thursday – January 27, 2022
3:00 pm | Establishing Immune Tolerance in Multiple Sclerosis Using Peptide-Coupled Red Blood Cells
Matthias von Herrath
Vice President & Senior Medical Officer, Global Chief Medical Officer
Novo Nordisk
Day One
Wednesday – January 26, 2022
2:00 pm | The Struggles with Immune Biomarkers and Pathologic Endotypes in Type 1 Diabetes
Charlotte Fribert
Chief Executive Officer
Toleranzia
Day Two
Thursday – January 27, 2022
9:30 am | Large Molecule Drug Development for the Treatment of Myasthenia Gravis
Evelien Schurgers
Associate Director Research
WORG Pharmaceuticals
Day Two
Thursday – January 27, 2022
2:30 pm | Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism
Jessica Grossman
Chief Executive Officer
IgGenix, Inc
Day One
Wednesday – January 26, 2022
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Vincent Carlier
Immunology Director
Imcyse
Day One
Wednesday – January 26, 2022
12:00 pm | Understanding the Mechanism of Action of Imotopes™ at Molecular and Cellular Level
James Moon
Co-Founder & Chief Scientific Officer; Professor of Pharmaceutical Sciences
EVOQ Therapeutics; University of Michigan
Day Two
Thursday – January 27, 2022
12:30 pm | A Novel NanoDisc Platform for Systemic Targeting of Lymphoid Tissues and Induction of Antigen-Specific Immune Tolerance
Asa Schott
Chief Scientific Officer
Idogen AB
Day Two
Thursday – January 27, 2022
11:30 am | A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Haemophilia A Patients
Bryan Vander Lugt
Senior Scientist
Amgen
Day One
Wednesday – January 26, 2022
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
8:50 am | Chair’s Opening Remarks
David Wraith
Founder & Chief Scientific Officer; Director, Institute of Immunology & Immunotherapy
Apitope; University of Birmingham
Day One
Wednesday – January 26, 2022
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Remi J. Creusot
Assistant Professor of Medical Sciences
Columbia University
Day One
Wednesday – January 26, 2022
11:30 am | Strategies for Epitope-Based Tolerance-Inducing Immunotherapy
Adam Elhofy
Director of Immunology
COUR Pharmaceuticals
Day One
Wednesday – January 26, 2022
3:30 pm | Antigen-Specific Tolerance to Multiple Epitopes in T1D
Ulf Hannelius
President & Chief Executive Officer
Diamyd Medical
Day One
Wednesday – January 26, 2022
4:00 pm | Precision Medicine and Antigens – The Case of HLA and GADSpecific Immunotherapy in Type 1 Diabetes
Klaus Ley
Professor/Division Head - Center for Autoimmunity & Inflammation
La Jolla Institute for Immunology
Day One
Wednesday – January 26, 2022
10:00 am | Inducing Tolerance to ApoB Epitopes to Curb Atherosclerosis
Wanjun Chen
Senior Investigator & Chief, Mucosal Immunology Section
NIDCR, NIH
Day One
Wednesday – January 26, 2022
9:30 am | Manipulation of TGF-β for Antigen-Specific Immunotherapy of Autoimmune Diseases
Stephen D. Miller
Judy Gugenheim Research Professor, Department of Microbiology- Immunology
Northwestern University Feinberg School of Medicine
Day One
Wednesday – January 26, 2022
2:30 pm | Requirement for Induced Tregs and Tr1 Cells or Regulation of Autoimmune Disease Using Antigen Encapsulating PLG Nanoparticles
Aaron Winkler
Research Fellow, Immune Tolerance Lead, Inflammation & Immunology
Pfizer, Inc.
Day Two
Thursday – January 27, 2022
8:50 am | Chair’s Opening Remarks
Klaus Martin
Chief Executive Officer
Topas Therapeutics
Day Two
Thursday – January 27, 2022
2:00 pm | A Nanoparticle Platform for Multiple Immune Tolerance Therapies
Rainer Henning
Chief Scientific Officer
WORG Pharmaceuticals
Day Two
Thursday – January 27, 2022
12:00 pm | The PCFiT Platform: A Promising Approach for B-Cell Directed Allergy Immunotherapy
Michael Yeaman
Professor of Medicine, Chief, Molecular Medicine, Director, Institute for Infection & Immunity; Lundquist Institute; Chair, Medical Sciences, Guthy-Jackson Charitable Foundation
UCLA
Day Two
Thursday – January 27, 2022
9:00 am | Facilitating Translation of Tolerization Technologies
Daniel Rotrosen
Director, Division of Allergy, Immunology & Transplantation
National Institute of Allergy & Infectious Diseases of Allergy & Infectious Diseases
Day One
Wednesday – January 26, 2022